Newsfeeds Archive - Spark Newswire

2 minute read

Diffusion Pharmaceuticals Stockholders Approve Merger With EIP Pharma; ~71% Of Stockholders Voted In Favor Of The Transaction; Announces 1-For-1.5 Reverse Stock Split

August 15, 4:13 PM

Approximately 71% of Stockholders Voted in Favor of the Transaction Diffusion Announces 1-for-1.5 Reverse Stock Split Merger on Track to Close on August 16, 2023 CHARLOTTESVILLE, Va., Aug. 15, 2023 (GLOBE

DFFN

8 minute read

Options

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

July 6, 12:58 PM

On Thursday, 109 companies set new 52-week lows.

AADI

7 minute read

Options

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

May 5, 1:54 PM

Friday's session saw 100 companies set new 52-week lows.

ACRX

24 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

April 26, 2:37 PM

On Wednesday, 345 companies set new 52-week lows.

ABCB

6 minute read

Options

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

April 3, 1:36 PM

On Monday, 76 companies set new 52-week lows.

ADV

1 minute read

News

Diffusion Pharmaceuticals Sends Letter To Stockholders Highlighting Strength Of Board Leadership And Positive Progress In Strategic Review, Cautioning Stockholders Regarding LifeSci’s History Of Stockholder Value Destruction And Self-Dealing

By Benzinga Newsdesk

December 5, 7:33 AM

Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review process Diffusion received bids from more than 15 companies participating in

DFFN

2 minute read

LifeSci Special Opportunities Responded to Recent Press Release Issued by Diffusion Pharmaceuticals

By Charles Gross

November 17, 6:21 PM

LifeSci Special Opportunities Master Fund Ltd. ("LifeSci Special Opportunities" or "we"), the holder of 96,976 shares of common stock of Diffusion Pharmaceuticals Inc.

DFFN

2 minute read

News

Diffusion Pharmaceuticals Announces Strategic Review Process To Evaluate Value-Enhancing Alternatives Including Opportunities To Better Leverage TSC

By Benzinga Newsdesk

October 25, 6:36 AM

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that may enhance the body's ability to deliver oxygen to areas

DFFN

1 minute read

HC Wainwright & Co. Upgrades Diffusion Pharmaceuticals to Buy, Announces $9.5 Price Target

By Benzinga Newsdesk

August 16, 6:26 AM

HC Wainwright & Co. analyst Swayampakula Ramakanth upgrades Diffusion Pharmaceuticals (NASDAQ:DFFN) from Neutral to Buy and announces $9.5 price target.

DFFN

1 minute read

Diffusion Pharmaceuticals To Initiate Phase 2 Trial In Patients With Glioblastoma Multiforme Incorporating Innovative Imaging Methodology To Evaluate Tumor Oxygenation

By Benzinga Newsdesk

July 26, 7:37 AM

Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”)

DFFN